



**C  
I  
P  
E  
JUN 28 2004  
PATENT & TRADEMARK OFFICE  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Inventors:</b>	Matthew C.T. FYFE et al.
<b>Serial No.:</b>	10/776,584
<b>Attorney Docket No.:</b> NC-10001	
<b>Filed:</b>	February 1, 2004
<b>Group Art No.:</b> unassigned	
<b>Examiner:</b>	unassigned
<b>Title:</b>	TRI(CYCLO)SUBSTITUTED AMIDE COMPOUNDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Mail Stop Amendment**, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI Pharmaceuticals, Inc.

By Shu M. Lee  
Shu M. Lee

Date June 24, 2004

**Mail Stop Amendment**  
Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

### **INFORMATION DISCLOSURE STATEMENT**

Applicants respectfully submit the documents itemized in the enclosed Form 1449 to the Examiner's attention. Copies of the documents, except for U.S. Patent documents – which the Patent Office has instructed Applicants not to submit, are also enclosed for the Examiner's review. Applicants respectfully request the Examiner initial the form and return a copy to the Applicant to indicate each document has been considered.

The significance of foreign language documents WO 03/080585 and WO 04/097824 is described in the specification at page 2, lines 26-31.

This IDS is being submitted before issuance of any Office Action on the merits. Accordingly, no fee is needed. Nevertheless, the Examiner is authorized to charge any deficiencies in fees and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. **502783**.

Attorney for Applicants can be reached at the telephone number and address below.

I hereby certify  
deposited  
with  
Postage  
Box  
1450,  
appearing below,

being  
with  
Postage  
Box  
date

OSI PHARMACEUTICALS, Inc.

By \_\_\_\_\_ Date \_\_\_\_\_

June 24, 2004

OSI Pharmaceuticals, Inc.  
58 South Service Road, Suite 110  
Melville, NY 11747

Respectfully submitted,



Shu M. Lee  
Attorney for Applicants  
Registration No. 41,147  
Telephone No. (631) 962-2056  
or (516) 924-4035  
Fax No. (631) 752-3880

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI PHARMACEUTICALS, Inc.

By Shu M. Lee Date 24 June 2004



Form TO-1449

**LIST OF PATENTS AND  
PUBLICATIONS FOR  
APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT**  
(Use as many sheets as necessary)

Sheet 1 of 2

**Complete If Known**

Application Number	10/776,584
Filing Date	February 1, 2004
First Named Inventor	Matthew C.T. FYFE
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket No.	NC-10001

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/ SUBCLASS
A1	6,320,050	11-20-2001	Bizzarro		
A2	6,353,111	03-05-2002	Corbett		
A3	6,369,232	04-09-2002	Sidduri		
A4	6,384,220	05-07-2002	Corbett		
A5	6,388,071	05-14-2002	Mahaney		
A6	6,388,088	05-14-2002	Sidduri		
A7	6,433,188	08-13-2002	Corbett		
A8	6,441,180	08-27-2002	Sidduri		
A9	6,441,184	08-27-2002	Corbett		
A10	6,448,399	09-10-2002	Corbett		
A11	6,482,951	11-19-2002	Guertin		
A12	6,486,184	11-26-2002	Kester		
A13	6,489,485	12-03-2002	Bizzarro		

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY
B1	WO 04/050645	06-17-2004	Novartis AG	PCT	
B2	WO 00/058293	10-05-2000	F. Hoffman-La Roche	PCT	
B3	WO 01/044216	06-21-2001	F. Hoffman-La Roche	PCT	
B4	WO 01/083465	11-08-2001	F. Hoffman-La Roche	PCT	
B5	WO 01/083478	11-08-2001	F. Hoffman-La Roche	PCT	
B6	WO 01/085706	11-15-2001	F. Hoffman-La Roche	PCT	
B7	WO 01/085707	11-15-2001	F. Hoffman-La Roche	PCT	
B8	WO 02/008209	01-31-2002	F. Hoffman-La Roche	PCT	
B9	WO 02/014312	02-21-2002	F. Hoffman-La Roche	PCT	
B10	WO 02/046173	06-13-2002	F. Hoffman-La Roche	PCT	
B11	WO 02/048106	06-20-2002	F. Hoffman-La Roche	PCT	
B12	WO 03/000262	01-03-2003	Astrazeneca AB	PCT	
B13	WO 03/000267	01-03-2003	Astrazeneca AB	PCT	

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
C1	R.L. Printz et al., Ann. Rev. Nutrition, 13:463-496(1993)	
C2	Y.Liang et al., Biochem. J., 309:167-173(1995)	
C3	H.B.T. Christesen et al., Diabetes, 51:1240-1246(2002)	
C4	Printout of Delphion Abstract for WO 03/97824	

EXAMINER	Date Considered:
----------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		Complete If Known		
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use as many sheets as necessary)		Application Number	10/776,584	
		Filing Date	February 1, 2004	
		First Named Inventor	Matthew C.T. FYFE	
		Art Unit	Unassigned	
		Examiner Name	Unassigned	
Sheet	2	of	2	
			Attorney Docket No.	NC-10001

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
	C5	Printout of Delphion Abstract for WO 03/080585

<b>EXAMINER</b>	Date Considered:
-----------------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.